Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries

Abstract

The COVID-19 pandemic has had an unprecedented and disruptive impact on people’s health and lives worldwide. In addition to burdening people’s health in the short-term in the form of infection, illness, and mortality, there has been an enormous negative impact on clinical research. Clinical trials experienced challenges in ensuring patient safety and enrolling new patients throughout the pandemic. Here, we investigate and quantify the negative impact that the COVID-19 pandemic has industry-sponsored clinical trials, both in the USA and worldwide. We find a negative correlation between the severity of the COVID-19 pandemic and clinical trial screening rate, with the relationship being strongest during the first three months of the pandemic compared to the entire duration of the pandemic. This negative statistical relationship holds across therapeutic areas, across states in the USA despite the heterogeneity of responses at the state-level, and across countries. This work has significant implications for the management of clinical trials worldwide in response to the fluctuating severity of COVID-19 moving forward and for future pandemics.

A randomized controlled trial comparing conservative versus surgical treatment in patients with foot drop due to peroneal nerve entrapment: results of an internal feasibility pilot study

“…In addition, the operating theatre availability was substantially decreased for non-life-threatening conditions or non-urgent surgical procedures. These findings are in accordance with the literature on the impact of COVID-19 on clinical trial screening rates [ 28 ], indicating that there is a negative correlation between the severity of the global pandemic and the number of screenings in clinical trials.…”

Impact of the COVID‐19 Pandemic on Conduct and Results of CLEAR Outcomes Trial

“…Another study of 321 218 non‐COVID‐19 clinical trials found that among trials stopped from January 2017 to May 2020, an average of 1147 trials per month were stopped during the start of the pandemic (the first 5 months of 2020), compared with 638 trials per month from 2017 to 2019 [ 7 ]. A more recent analysis sought to quantify the impact of the pandemic on industry‐sponsored clinical trials, demonstrating that year‐over‐year clinical trial screening rates declined sharply from 2019 to 2020, with a slight rebound in 2021 [ 8 ].…”

Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial

“…We initially planned to enroll 100 patients into this study based on power calculations of possible differences between groups in cognition and function after 20 weeks. However, due to challenges in recruiting patients, especially with the COVID-19 emergency and that many pharma trials began recruiting patients with similar criteria, it took longer to enroll patients than initially planned [21]. Because of this, we terminated recruitment after 51 patients were enrolled.…”